Department of Diagnostic Imaging, Department of Radiology, Penn State Health Milton S Hershey Medical Center, Penn State University Hospital, 500 University Dr, Hershey, PA 17033-0850 (E.S.); Department of Diagnostic Imaging, Hadassah Hebrew University Medical Center, Jerusalem, Israel, Affiliated with the Hebrew University Medical School, Jerusalem, Israel (Y.A., J.M.G., S.F., T.S.); and Department of Diagnostic Imaging, Edith Wolfson Medical Center, Holon, Israel, Affiliated with the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel (T.A.K.).
Radiol Imaging Cancer. 2020 Nov 6;2(6):e200004. doi: 10.1148/rycan.2020200004. eCollection 2020 Nov.
To understand and remove the source of a phase-wrap artifact produced by residual contrast agent in the intravenous line during acquisition of bilateral axial 3-T dynamic contrast material-enhanced (DCE) breast MRI.
A two-part study involved a phantom experiment, followed by an institutional review board approved clinical intervention, to evaluate the phase-wrap artifact at MRI. A phantom model evaluated artifact production by using an intravenous line filled with fluids with varying concentrations of gadolinium-based contrast agent (0, 0.4, 0.8, 1.2, 1.6, and 2 mmol/mL) and by positioning the simulated intravenous line within several fields of view (FOV) at 3-T MRI in breast coils. Next, a clinical assessment was performed with a total of 400 patients (control group:interventional group, 200:200) to determine the effect of taping the intravenous line to the patients' backs. Breast MR images were assessed blindly for the presence of the artifact. Software was used for statistical analysis with a value of less than .05 considered a significant difference.
In the phantom model, the artifact was produced only with a 0.4 mmol/mL gadolinium concentration and when the tubing was either close to the edge or within a FOV of 350-450 mm. In the clinical experiment, the artifact was more prevalent in the retrospective control group than in the prospective intervention group (52.5% [105 of 200] vs 22% [44 of 200]; < .005).
The presence of phase-wrap artifacts can be reduced by moving the contrast agent intravenous line out of the FOV during acquisition by taping it to a patient's back during bilateral axial 3-T DCE breast MRI. Breast, MR-Imaging, Phantom Studies© RSNA, 2020.
了解并消除在 3T 双侧轴向动态对比增强（DCE）乳腺 MRI 采集过程中，静脉内残留造影剂引起的相位缠绕伪影的来源。
本研究包括两部分，一部分是使用充满不同浓度钆基造影剂（0、0.4、0.8、1.2、1.6 和 2mmol/mL）的静脉管路进行的一项体模实验，另一部分是对该静脉管路分别置于乳腺线圈 3T MRI 多个视野（FOV）内进行的一项机构审查委员会批准的临床干预，以评估 MRI 相位缠绕伪影。接下来，对总共 400 例患者（对照组：干预组，200：200）进行了临床评估，以确定将静脉管路粘贴到患者背部对该伪影的影响。盲法评估乳腺 MR 图像中伪影的存在。使用软件进行统计分析， <.05 被认为具有统计学意义。
在体模模型中，仅在 0.4mmol/mL 钆浓度且当导管靠近边缘或位于 350-450mm 的 FOV 内时，才会产生伪影。在临床实验中，与回顾性对照组相比，前瞻性干预组的伪影更为常见（52.5%[200 例中的 105 例]比 22%[200 例中的 44 例]； <.005）。
通过在双侧轴向 3T DCE 乳腺 MRI 采集期间将造影剂静脉管路粘贴到患者背部，使其移出 FOV，可以减少相位缠绕伪影的出现。
乳腺；磁共振成像；体模研究 ©RSNA，2020。
